Pdt Partners, LLC Mirati Therapeutics, Inc. Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $624,690 - $910,263	-10,499 Reduced 27.67%	27,445 $1.92 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $1.49 Million - $3.37 Million	37,944 New	37,944 $2.55 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $338,340 - $471,807	-2,129 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $345,004 - $511,534	2,129 New	2,129 $468,000
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $625,590 - $1.26 Million	-24,015 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $20,794 - $42,254	-1,209 Reduced 4.79%	24,015 $737,000
Q4 2017 Feb 14, 2018	SELL	$12.65 - $19.0 $543,646 - $816,544	-42,976 Reduced 63.01%	25,224 $460,000
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $320,540 - $797,940	68,200	68,200 $798,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.